Aponermin or Placebo in Combination with Thalidomide and Dexamethasone in the Treatment of Relapsed or Refractory Multiple Myeloma (CPT-MM301): a Randomised, Double-Blinded, Placebo-Controlled, Phase 3 Trial Zhongjun Xia , Yun Leng , Baijun Fang , Yang Liang , Wei Li , Chengcheng Fu , Linhua Yang , Xiaoyan Ke , Hua Jiang , Jianyu Weng , Li Liu , Yaozhong Zhao , Xuejun Zhang , Zhongxia Huang , Aichun Liu , Qingzhi Shi , Yuhuan Gao , Xiequn Chen , Ling Pan , Zhen Cai , Zhao Wang , Yafei Wang , Yaqun Fan , Ming Hou , Yigai Ma , Jianda Hu , Jing Liu , Jianfeng Zhou , Xiaohong Zhang , Haitao Meng , Xuzhang Lu , Fei Li , Hanyun Ren , Bintao Huang , Zonghong Shao , Hebing Zhou , Yu Hu , Shifang Yang , Xiangjun Zheng , Peng Wei , Hongyan Pang , Wei Yu , Yuzhang Liu , Sujun Gao , Lingzhi Yan , Yanping Ma , Hongmei Jing , Juan Du , Wei Ling , Jingyi Zhang , Weiwei Sui , Fuxu Wang , Xin Li , Wenming Chen BMC CANCER（2023）
关键词
Aponermin, TNF-related apoptosis-inducing ligand, Multiple myeloma, Relapsed/refractory, Phase 3
AI 理解论文
溯源树
样例
